Comparing Antibodies for Colorectal Cancer Detection
Author Information
Author(s): S.D. Blair, N.A. Theodorou, R.H.J. Begent, P.M. Dawson, M. Salmon, S. Riggs, A. Kelly, G. Boxer, P. Southall, P. Gregory
Primary Institution: Charing Cross Hospital, London
Hypothesis
Peroperative radioimmunolocalisation may improve the assessment of colorectal cancer during surgery.
Conclusion
The anti-CEA monoclonal antibody A5B7 shows significantly better uptake in colorectal tumors compared to the anti-fetal microvillus antibody FMID10.
Supporting Evidence
- 98% of tumors labeled with A5B7 showed significant antibody uptake.
- 69% of tumors labeled with FMID10 showed significant antibody uptake.
- The median tumor to normal colon ratio was significantly higher for A5B7 than for FMID10.
- Results suggest A5B7 can improve surgical outcomes by better identifying tumor extent.
Takeaway
Doctors are testing two special antibodies to see which one helps find cancer better during surgery. One worked much better than the other.
Methodology
Fifty patients with colorectal carcinoma received either FMID10 or A5B7 antibodies, and their tumor uptake was measured using a gamma detecting probe.
Limitations
The study was limited by the small sample size and the preliminary nature of the findings.
Participant Demographics
24 males and 26 females, median age 69 years (range 38-82 years).
Statistical Information
P-Value
p<0.001
Confidence Interval
1.1-13.8
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website